


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+8.75%
-0.49%
-1.56%
-7.00%
ABT
Abbott Laboratories
$108.27
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Trading below its fair value

Investors confidence is positive
ABT Price Performance
$125.78 (-13.92%)
$123.62 (-12.42%)
$132.94 (-18.56%)
$130.49 (-17.03%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings

Below analyst estimate

Reported a strong earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity

Investors confidence is positive
Future
Future

Earnings are forecast to grow

Trading below its fair value
![]()
ABT Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
ABT Street Sentiment is bullish and have positive views on the near-term outlook
ABT has Low risk level

Average key support and resistance price levels
MRK
107.92
+0.51%
CVKD
7.62
-1.04%
PFE
26.50
+2.40%
AZN
95.60
+1.45%
OGN
9.00
-1.15%
What is ABT current stock price?
What are ABT stock strengths?
What is ABT Risk Level?
What is ABT market cap and volume?
What is ABT current Stock IQ?
Should I buy ABT stock right now?
Is ABT a Strong Buy right now?
What does a 'Strong Buy' rating mean for ABT?
What does a 'Strong Sell' rating mean for ABT?
What factors influence ABT's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+8.75%
-0.49%
-1.56%
-7.00%
ABT
Abbott Laboratories
Current Price
$108.27
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Trading below its fair value

Investors confidence is positive
Linked to ABT
MRK
107.92
+0.51%
CVKD
7.62
-1.04%
PFE
26.50
+2.40%
AZN
95.60
+1.45%
OGN
9.00
-1.15%
Recently Viewed
ABT
Abbott Laboratories
108.27
-0.46%
QBTS
D-Wave Quantum
24.69
+4.07%
TLRY
Tilray
8.42
-3.55%
MRVL
Marvell Technology Group
82.93
+1.42%
KDP
Keurig Dr Pepper
27.59
-0.40%

ABT Price Performance
$125.78 (-13.92%)
$123.62 (-12.42%)
$132.94 (-18.56%)
$130.49 (-17.03%)
ABT Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings

Below analyst estimate

Reported a strong earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity

Investors confidence is positive
Future
Future

Earnings are forecast to grow

Trading below its fair value
![]()
ABT Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
ABT Street Sentiment is bullish and have positive views on the near-term outlook
ABT has Low risk level

Average key support and resistance price levels
Overall Wall Street Rating
STRONG BUY
Nov 20, 2025
Reiterate
Buy
BTIG
Oct 17, 2025
Reiterate
Overweight
Wells Fargo
Oct 17, 2025
Reiterate
Outperform
RBC
Oct 17, 2025
Reiterate
Outperform
Raymond James
Oct 17, 2025
Reiterate
Outperform
Evercore ISI
ABT Stock IQ
ABT Latest Analysis
Greg Abbott Imposes Sweeping Ban On Texas Employees Using Products And Services From Alibaba Shein And Temu. On Monday Gov. In a statement Abbott said that Texas state employees are prohibited from using products and services from companies including BABA) and The reason cited is concerns that the Chinese government could gain access to sensitive data.The restriction applies to physical hardware software and artificial intelligence tools.The governor said the move is aimed at protecting the priv
Today
Evercore ISI Says Abbotts (ABT) Core Growth Drivers Are Still Intact. Abbott Laboratories (NYSE:ABT) is included among the 12 Most Profitable Dividend Stocks to Buy in 2026. On January 23 Evercore ISI trimmed its price target on Abbott Laboratories (NYSE:ABT) to $138 from $144. However it kept an Outperform rating. The firm acknowledged the recent stumbles that led to a quarterly miss and a more cautious [….]
Mon Jan 26, 2026
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It. Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus it is worth knowing the facts that could determine the stocks prospects.
Mon Jan 26, 2026
Monday 1/26 Insider Buying Report: ABT ALLY. As the saying goes there are many possible reasons for an insider to sell a stock but only one reason to buy -- they expect to make money. So lets look at two noteworthy recent insider buys.At Abbott Laboratories a filing with the SEC revealed that on Friday CHAIRMAN AND
Mon Jan 26, 2026
3 Reasons to Buy This Dividend King After Its Steep Sell-Off. Key PointsAbbotts stock plunged after the company reported lower-than-expected Q4 revenue last week.
Mon Jan 26, 2026
Abbotts India Unit Under Scrutiny Due To Phensedyl Cough Syrup Supply Chain. Indian authorities are scrutinizing the supply chain of Abbott Healthcare halted production of Phensedyl in December 2024 citing persistent misuse despite safeguards. However the drug is reportedly active within existing supply channels.Regulators claim large volumes continue to circulate in the market raising concerns about non-therapeutic use and possible abuse.Phensedyl contains codeine a narcotic commonly used in b
Fri Jan 23, 2026
Abbott (ABT) is a Top-Ranked Value Stock: Should You Buy?. The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why you should take advantage.
Fri Jan 23, 2026
Abbott Laboratories: Buy This Dividend King On Sale Now.
Fri Jan 23, 2026
Abbott Stock Slides 7% After Q4 Results And 2026 Outlook Disappoint Investors . (RTTNews) - Abbott Laboratories (ABT) shares fell 6.51% trading at $112.87 down $7.86 after the company reported its fourth quarter and full year 2025 results and issued its financial outlook for 2026.
Thu Jan 22, 2026
Abbott Laboratories Enters Oversold Territory. The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks according to a proprietary formula designed to identify those stocks that combine two important characteristics &mdash. strong fundamentals and a valuation that looks inexpensive.
Thu Jan 22, 2026
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.